Genomic instability is the increased tendency for DNA mutations and other genetic changes to accumulate during cell division. It happens when the systems your cells use to copy and repair DNA stop working correctly, allowing errors to pile up over time. This process is a defining feature of cancer, present in over 90% of solid tumors, and understanding it helps explain both why cancer develops and how some modern treatments work.
How Genomic Instability Works
Every time a cell divides, it copies roughly 3 billion base pairs of DNA. That copying process is remarkably accurate, but it’s not perfect. Cells rely on several repair systems to catch and fix mistakes: some correct single-letter typos in the genetic code, others patch broken strands, and still others handle larger structural problems like misaligned chromosomes. Genomic instability sets in when one or more of these repair systems fails.
The damage can show up at different scales. At the smallest level, individual letters of the DNA code get swapped, inserted, or deleted. At a mid-range level, short repetitive sequences in DNA (called microsatellites) expand or contract because the mismatch repair system that normally keeps them in check isn’t functioning. At the largest scale, entire chromosomes can break, fuse together, go missing, or appear in extra copies. This chromosomal form of instability is the most common type seen in cancer.
What Causes It Inside the Cell
One major internal driver is replication stress. This occurs when the molecular machinery copying DNA slows down or stalls, often because it runs into obstacles like DNA damage, unusual DNA structures, or collisions with the machinery that reads genes to make proteins. When replication forks stall, they can collapse and leave behind broken DNA that the cell may repair incorrectly, introducing mutations or rearrangements.
Reactive oxygen species, the chemically reactive molecules your cells produce as byproducts of normal metabolism, also play a significant role. Elevated levels of these molecules slow down the DNA-copying machinery by knocking loose a key stabilizing complex (called TIMELESS-TIPIN) from the replication fork. This forces the fork to reverse direction, and if protective proteins like BRCA1 and BRCA2 are missing, the exposed DNA gets chewed up by cellular enzymes. Research published in Nature Communications showed that this link between oxidative stress and replication interference is a major source of the chromosomal rearrangements commonly found in human cancers.
Telomeres, the protective caps on chromosome ends, are another vulnerability. Each time a cell divides, telomeres get slightly shorter. When they become critically short, chromosomes lose their protective coating and can fuse end-to-end. During the next cell division, the fused chromosomes get pulled in opposite directions, forming a bridge that eventually snaps. The break rarely occurs at the original fusion point, so each cycle of breakage, fusion, and bridging shuffles genetic material to new locations. This process can repeat over many generations of cells, progressively scrambling the genome.
Environmental Triggers
External factors can accelerate genomic instability by directly damaging DNA or overwhelming repair systems. Ultraviolet radiation from sunlight causes specific types of DNA damage linked to skin cancer. Tobacco smoke introduces dozens of chemicals that damage DNA in lung tissue. Aflatoxin B1, a toxin produced by mold on improperly stored grains and nuts, targets liver cells and drives liver cancer. These are among the best-studied examples, but many common environmental chemicals are genotoxic, meaning they cause DNA damage that, if not repaired correctly, feeds into the cycle of accumulating mutations.
Why It Matters for Cancer
Genomic instability is considered an enabling characteristic of cancer, not just a side effect of it. The “mutator phenotype” hypothesis, proposed by Lawrence Loeb in the early 1990s, argues that instability is already present in precancerous lesions, where it dramatically increases the rate of spontaneous mutations. This creates a large pool of genetically diverse cells, and natural selection does the rest: cells that happen to acquire mutations giving them a growth advantage, or the ability to dodge the immune system, outcompete their neighbors and expand.
A complementary model focuses on oncogene-induced replication stress. When genes that promote cell growth become overactive early in tumor development, they push cells to divide faster than the replication machinery can handle. The resulting replication stress generates DNA damage. Cells that lose their normal safety checkpoints (which would ordinarily force damaged cells to stop dividing or self-destruct) survive and keep accumulating damage, creating an escalating cycle of instability and selection. In this way, genomic instability gives cancer cells the raw material to evolve rapidly, acquiring resistance to drugs, the ability to invade other tissues, and other dangerous traits.
How Doctors Measure It
Two main biomarkers help clinicians assess genomic instability in a tumor. The first is microsatellite instability (MSI) status, which reveals whether the mismatch repair system is broken. Tumors with high MSI accumulate mutations in those short repetitive DNA sequences at a much higher rate than normal cells. This marker is routinely tested in colorectal and endometrial cancers and helps guide treatment decisions, particularly for immunotherapy.
The second is a homologous recombination deficiency (HRD) score, which measures how well a tumor can repair double-strand DNA breaks using its most accurate repair pathway. When this pathway fails, typically because of mutations in genes like BRCA1 or BRCA2, tumors develop characteristic patterns of large-scale DNA rearrangements. Clinicians look at three specific signatures: loss of heterozygosity (stretches where one copy of DNA is lost), telomeric allelic imbalance (uneven DNA near chromosome ends), and large-scale state transitions (breaks between regions of different copy numbers). Commercial tests combine these signatures into a single score. The two most widely validated are the Myriad myChoice assay and the Foundation Focus CDx BRCA LOH assay, both of which have been used to select patients for targeted therapies in clinical trials.
Treatments That Exploit Instability
One of the most practical consequences of understanding genomic instability is that it opened the door to therapies that turn a tumor’s broken repair systems against it. The clearest example is the class of drugs called PARP inhibitors. PARP is a protein that helps repair single-strand DNA breaks. When you block PARP in a cell that also can’t fix double-strand breaks (because BRCA1 or BRCA2 is mutated), the cell accumulates so much unrepaired damage that it dies. Normal cells, which still have functioning repair pathways, survive. This concept, called synthetic lethality, has made PARP inhibitors a standard treatment for certain ovarian, breast, pancreatic, and prostate cancers.
A newer class of drugs targets ATR, a protein that cancer cells rely on to manage replication stress. When ATR is blocked, stalled replication forks collapse in large numbers, overwhelming the cell and triggering what researchers call “replication catastrophe.” Cancer cells with high levels of replication stress are particularly vulnerable because they depend on ATR more than healthy cells do. Preclinical studies show that combining ATR inhibitors with PARP inhibitors can overcome resistance to either drug alone, including in BRCA-deficient cancers that have stopped responding to PARP inhibitors or platinum chemotherapy. Several combinations are now in clinical trials.
Tumors with high microsatellite instability also respond well to immunotherapy. Their high mutation rate generates many abnormal proteins on the cell surface, making them more visible to the immune system. Immune checkpoint inhibitors, which remove the brakes that normally prevent immune cells from attacking, are particularly effective against these highly mutated tumors regardless of where in the body the cancer originated.
Inherited vs. Acquired Instability
Some people are born with mutations that predispose them to genomic instability. Inherited BRCA1 and BRCA2 mutations are the most well-known examples, significantly increasing the risk of breast, ovarian, pancreatic, and prostate cancers. Lynch syndrome, caused by inherited defects in mismatch repair genes, leads to high microsatellite instability and elevated risk of colorectal and endometrial cancers. Current clinical guidelines recommend genetic counseling and testing for individuals whose personal or family history suggests they may carry these variants, with specific screening protocols tailored to each gene.
In most cancers, though, genomic instability is acquired rather than inherited. It develops gradually as cells accumulate damage from replication errors, oxidative stress, environmental exposures, and aging. The distinction matters because inherited instability can be identified before cancer develops, allowing for earlier screening and preventive strategies, while acquired instability is typically detected only after a tumor has formed.